Clario’s Otis Johnson, Ph.D., honored as impact leader finalist by Informa’s Biotech Week Boston Awards
Chief Diversity, Inclusion, and Sustainability Officer recognized for their environmentally-conscious efforts towards sustainability and good governance
PHILADELPHIA, PA – October 6, 2022 –, Clario, a technology company that delivers the leading endpoint solutions for decentralized (DCT), hybrid and site-based clinical trials, announced that Otis Johnson, Ph.D., Chief Diversity, Inclusion, and Sustainability Officer, has been recognized as a finalist for the Impact Leader Award at Informa’s Biotech Week Boston (BWB) Awards. The BWB Impact Leader award is in recognition of environmentally conscious efforts toward sustainability and good governance.
“We do not believe enough is being done to measure and reduce the carbon footprint of the clinical trial industry, so we have stepped up to measure and reduce our environmental impact. We are firm in the knowledge that healthy patients can only thrive on a healthy planet.“
“The BWB Impact Leader award recognition comes because of strong contributions from all Clario’s people, from our interns through to the CEO. We needed accurate data from suppliers and thousands of employees to understand the true impact of our global operations. Collaboration, transparency and accuracy are key enablers for Clario,” said Dr. Johnson.
Within a year, highly engaged employees made it possible for the organization to:
- Robustly measure its carbon footprint and identify targeted areas for emission reductions
- Reduce its global office footprint
- Switch its largest facility to 100% green energy
- Redesign products and packaging for efficiency and reduced environmental impact
- Adjust its service delivery models and logistics
- Create new value out of retired devices and technology through donations
“Through our own operations, we have the power to reduce health disparities and do so while positively impacting the planet. Clario’s go-forward strategy on our journey to net-zero is data driven and grounded in science. We aspire to be good corporate citizens to both people and planet”, said Dr. Johnson.
Dr. Johnson was recently named to the prestigious Pharmavoice100 list of most inspiring life-science industry leaders, and named a Mogul Top 100 Diversity, Equity and Inclusion (DEI) leader for his significant contributions to increasing the diversity of clinical trial participants and throughout the clinical trial workforce. He applied the same winning DEI approach to his environmental strategy, going after the data and actionable business insights, to form a multiyear strategy with specific and measurable environmental goals.
The BWB Awards recognize individuals and organizations who have made positive and innovative contributions to the life sciences industry. Finalists were recognized and winners were announced at a ceremony in Boston, MA on September 27.
Learn more about Clario’s environmental, social, and governance (ESG) work.
About Clario
Clario is a leading healthcare research and technology company that generates the richest clinical evidence in the industry for our pharmaceutical, biotech and medical device partners. Across decentralized, hybrid and site-based trials, our deep scientific expertise, global scale and the broadest endpoint technology platform in the industry allows our partners to transform lives. Clario has the only technology platform that combines eCOA, cardiac safety, medical imaging, precision motion, and respiratory endpoints. Clario’s global team of science, technology and operational experts have helped deliver more than 27,000 trials and contributed to over 500 FDA and EMEA new drug approvals involving more than seven million participants in over 100 countries. Our innovation has been transforming clinical trials for 50 years.
For more information, go to Clario.com or follow us on LinkedIn and Twitter.
Clario Media Contact
Duncan Cantor
Snr. Director, Content and Communications
[email protected]
+44 7307 533 162